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design and followed rosacea patients enrolled in North Carolina
Medicaid and who were prescribed at least one study medication
(topical metronidazole, adapalene, azelaic acid, permethrin, and
sulfacetamide). Patients’ demographic characteristics, number of
metronidazole reﬁlls, and different components of health care
costs were examined. Multivariate regression analyses were used
to examine factors associated with prescription reﬁlls and health
care costs. RESULTS: Out of the total 2587 rosacea patients,
the majority (~69%, n = 1771) had 1 or more prescriptions for
topical metronidazole. Most of the patients in this study were
Whites (73%). After controlling for other variables, increasing
age was associated with higher number of metronidazole reﬁlls
and health care costs (both p < 0.001). As compared to Whites,
African American patients had signiﬁcantly lower number of
metronidazole reﬁlls (p < 0.001). As compared to Whites,
African American and other races were associated with an 8.6%
and 10.3% decrease in total health care costs respectively (both
p < 0.001). An increase in number of metronidazole reﬁlls was
not associated with an increase in health care costs. CONCLU-
SIONS: Patients’ race was signiﬁcantly associated with the
number of topical metronidazole reﬁlls. Patients’ health care
costs increased with increasing age and charges paid for prescrip-
tions. Topical metronidazole seems to be an economically fea-
sible treatment option for Medicaid-enrolled patients with
rosacea.
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RETROSPECTIVE CHART REVIEWTO ASSESS
IMPLEMENTATION OF NICE GUIDANCE ONTHE USE OF
BIOLOGICALTHERAPIES IN PATIENTS WITH CHRONIC
PLAQUE PSORIASIS
Chauhan D1, Drakard M2,Velangi S3, Ralston SJ1
1Merck Serono, Feltham, UK, 2Interface Clinical Services, Burley in
Wharfdale, UK, 3City Hospital, Birmingham, UK
OBJECTIVES: To assess the use of biologicals for psoriasis
according to NICE technology appraisal 103 and assess actual
treatment practice within the NHS. METHODS: To date 13 UK
sites have enrolled into the chart review. Site selection was based
upon recruiting three centres with prescribers of biologicals
across nine geographical locations. Information was collected
for patients initiated on a biological between August 2006 and
December 2007 for plaque psoriasis. Patients were excluded if
they had a diagnosis of psoriatic arthritis. The data was collated
on demographics, co-morbidities, treatment courses, Psoriasis
Area Severity Index (PASI) and Dermatology Life Quality Index
(DLQI), and reasons for stopping treatment. Data was analysed
to ascertain adherence to NICE, and to explore regimens used in
practice and discontinuation rates. RESULTS: Recruitment is
being completed. This information will be reported as a full
dataset in the poster. Thus far data has been collected for 66
patients across 7 centres. The average age of patients reported
was 46 years. Eight-one percent of patients were initiated on
etanercept 25 mg twice weekly, 3% on etanercept 50 mg twice
weekly, and 8% on efalizumab. Of those patients who initiated
etanercept 25 mg twice weekly, the average length of the ﬁrst
course of treatment was 169 days (approximately 24 weeks).
Patients discontinued etanercept treatment for various reasons
including adverse events and lack of efﬁcacy. Fourteen switched
to efalizumab following ﬁrst etanercept course. Many patients
did not have PASI and DLQI recorded 12 weeks post treatment
commencement. CONCLUSIONS: Many of the NICE criteria
for prescribing biologicals have been followed; however there are
some areas which require focus including recording of PASI and
DLQI scores within three months. The review also showed that
the intermittent dosage assumed by NICE in the appraisal of
these drugs may not be realistic and modiﬁcation is needed in
further technology appraisals.
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A SCORING SYSTEM FOR QUALITY OF CARE EVALUATION.
A COMMUNITY-BASED STUDY OF CHRONIC LEG ULCERS IN
NORTH GERMANY
Augustin M1, Grams L1, Herberger K1, Franzke N1, Debus S2,
Rustenbach SJ1
1University Clinics of Hamburg, Hamburg, Germany, 2Asklepios Klinik
Harburg, Hamburg, Germany
OBJECTIVES: Evaluation of quality of care of leg ulcers in the
area of Hamburg, assessment of treatment with respect to
guidelines, recording of patients’ quality of life and burden of
treatment in the area of this community. METHODS: Potential
criteria for the evaluation of quality of care were derived from
the German AWMF-guideline and relevant international guid-
ance. Wound experts (physicians and nurses) derived 20 prior-
ity criteria and indicators which deﬁne “optimal treatment” in
a national Delphi consensus. A total score for quality of care
was developed, ranging from 0–100 (no to perfect quality of
care). Then, a representative sample of n = 520 patients with
chronic leg ulcers of any origin was consecutively drawn.
Patients were approached in wound clinics, ofﬁce-based prac-
tices, nursing homes, home care services and special centres for
homeless and drug addicts, thus including a large spectrum of
220 health care providers. All patients were interviewed, all
wounds photographed and examined by trained wound
experts. Patients were asked to ﬁll a questionnaire addressing
quality of life, prior therapy and health services/care.
RESULTS: Data of 502 patients were analysed, including leg
ulcers with venous (63%), mixed (23%), vasculitic (2%) and
other (12%) pathogenesis. A high proportion of patients
(78.6%) were treated with modern wound dressings. Pain and
compression therapy was mainly in accordance with guidelines.
However, deﬁcits were detected for diagnostics (e.g. angiology,
biopsies, pain measurement) and concomitant wound treat-
ments. A high proportion of patients still had a markedly
impaired quality of life. The mean total score for quality of
care was below 60. CONCLUSIONS: In spite of mostly “lege
artis” topical treatment, many patients in North Germany are
not treated in accordance to relevant guidelines. The quality of
care scoring method developed was shown to be a sensitive tool
for health services research and evaluation.
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IMPACT OF HEALTH CARE REGULATION ON
PROSTAGLANDIN ANALOGUE PRESCRIBING IN
5 EUROPEAN COUNTRIES
De Natale R1, Berdeaux G2
1Padova Hospital, Padova, Italy, 2Alcon France, Rueil-Malmaison, France
OBJECTIVES: To compare the evolution of prostaglandin ana-
logue (PGA) and beta-blocker (BB) prescriptions in ﬁve European
countries in the context of the health care regulation environ-
ment. METHODS: Data from different sources were gathered: 1)
1998–2003 prescriptions delivered by the central pharmacy of
the Padova geographical area; 2) IMS data (1995–2006) from
France, Germany, Italy, Spain and the United-Kingdom; and 3)
an extraction of glaucoma-treated patients from the UK-GPRD.
Drugs were grouped in 3 classes: PGA, BB and others. Yearly
market shares were calculated. Treatment persistence survival
curves were estimated from the Italian and UK data and the three
drug groups were compared using the Cochran Mantel Haenszel
test. RESULTS: According to the Padova data, BB market share
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decreased while PGA increased. A 1998–2003 linear extrapo-
lated market share would have predicted a crossing of the two
curves around 2005, reinforced by the new 1st line indication of
PGA authorized by the EMEA in 2002. This did not occur which
might be explained by the non-reimbursement of PGA for ﬁrst
line therapy in Italy. Accordingly, yearly Padova area drug spend-
ing was €150,000 less than predicted, on a €600,000 yearly
budget. The comparison of IMS data shows two countries where
the BB are still prescribed more than PGA, Italy and Germany.
The latter is a country where physicians’ fees are reduced if their
glaucoma prescription costs exceed their government set budget.
PGA monotherapy treatment persistence was longer than with
BB, according to Padova and UK GPRD data, in PGA-naive
patients. This holds true for ﬁrst line and second line treatment
(UK GPRD); the persistency of a second line PGA equaled ﬁrst
line BB treatment. A short treatment persistency is known to be
associated with high cost and disease progression. CONCLU-
SIONS: Health care regulation impacted glaucoma prescribing
and might be one of the reasons for differences observed between
the ﬁve European countries. Evaluations of both the cost conse-
quences beyond the drug budget and the public health impact
should always accompany the establishment of health care
regulations.
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DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE
THAN PSORIASIS AREA AND SEVERITY INDEXTO MEASURE
TREATMENT EFFECT IN PATIENTS WITH PSORIASIS:
FINDINGS FROMTHE PHOENIX ITRIAL
Lebwohl M1, Schenkel B2, Han C2, Papp KA3, Krueger GG4
1Mount Sinai School of Medicine, New York, NY, USA, 2Johnson and
Johnson Pharmaceutical Services, LLC, Horsham, PA, USA, 3Probity
Medical Research,Waterloo, ON, Canada, 4University of Utah Health
Sciences Center, Salt Lake City, UT, USA
OBJECTIVES: This analysis evaluated whether the Dermatology
Life Quality Index (DLQI) and the Psoriasis Area and Severity
Index (PASI) have different responsiveness to measure change
of treatment effect in moderate to severe psoriasis patients.
METHODS: In PHOENIX I, 766 patients were randomized to
ustekinumab 45 mg or 90 mg at weeks 0 and 4 and then q12
weeks thereafter, or placebo at weeks 0 and 4 with crossover
to ustekinumab at week 12. Ustekinumab-randomized patients
achieving PASI75 response at weeks 28 and 40 were re-
randomized at week 40 to continue maintenance ustekinumab or
be withdrawn from treatment until loss of response. DLQI and
PASI were assessed at weeks 0, 2, 12, 28, 40 and 52. Multiple
regression models were used to assess treatment effect on DLQI
by adjusting for PASI improvement. RESULTS: Signiﬁcantly
greater proportions of patients receiving ustekinumab achieved
PASI75 response (66.7%) and clinically meaningful improve-
ment (5 points) in DLQI (67.8%) compared with placebo
(3.1% and 6.0%, each p < 0.001) at week 12. There was a
signiﬁcant correlation between the change in DLQI and change
in PASI (r = 0.65, p < 0.001). After adjustment for baseline
DLQI, baseline PASI, and change in PASI, ustekinumab was still
associated with signiﬁcant improvement in DLQI (p < 0.001).
For patients originally randomized to ustekinumab, the median
% improvement from baseline was higher in DLQI (37.5%) than
in PASI (21.4%) at week 2, with 11.4% of patients achieving a
DLQI score of 1, but only 1% achieving a PASI75 response. At
week 28 and 40, the DLQI and PASI achieved and maintained
similar improvements of 90% from baseline. For those who
achieved and maintained a PASI75 response from week 12
through week 40, but lost response at week 52, the median
improvement in DLQI decreased more signiﬁcantly (100% at
week 40 to 46% at week 52, a 54% reduction) than PASI that
decreased from 88.9% at week 40 to 57.6% at week 52 (35.0%
reduction). CONCLUSIONS: The DLQI may be more respon-
sive to change of disease status due to treatment intervention
than PASI.
SYSTEMIC DISORDERS/CONDITIONS—
Clinical Outcomes Studies
PSY1
A SYSTEMATIC REVIEW OFTHE EFFICACY OF
RECOMBINANT ACTIVATED FACTORVII (RFVIIA) AND
ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE
(APCC) INTHE ON-DEMANDTREATMENT OF MINORTO
MODERATE BLEEDING EPISODES FOR HAEMOPHILIA
PATIENTS WITH INHIBITORS
Knight C1, Dano AM2, Kennedy-Martin T3
1RTI Health Solutions, Manchester, UK, 2Novo Nordisk A/S,Virum,
Denmark, 3KMHO, Brighton, UK
OBJECTIVES: The primary treatment for minor to moderate
bleeding disorders in haemophilia patients with inhibitors is
either rFVIIa or aPCC. The efﬁcacy of both products has been
evaluated in individual studies; however there has not been an
overall review and attempt to establish a valid estimate of the
effectiveness of rFVIIa and aPCC. We undertook a systematic
review of the literature in an attempt to establish robust estimates
of the efﬁcacy, speed of bleed resolution, and adverse event
proﬁle of both rFVIIa and aPCC. METHODS: We identiﬁed 11
open-label cohort studies, six randomized clinical trials, includ-
ing two head-to-head clinical trials and a meta-analysis. The
deﬁnition of efﬁcacy varies between these studies, but is usually a
composite measure of deﬁnite relief of pain, reduction in the size
of the haemorrhage, and cessation of bleeding. The individual
making the interpretation of efﬁcacy (i.e., the clinician, the
patient/caregiver, or a combination of both) and the time from
treatment initiation to the recording of the efﬁcacy endpoint also
varies across the studies. RESULTS: Overall, estimates of efﬁcacy
based on randomized clinical trials using dosing regimens in line
with guidelines are higher for rFVIIa (81%–91%) than for aPCC
(64–80%). Conclusions from a meta-analysis suggest that treat-
ment with rFVIIa may be associated with a faster time to joint
bleed resolution than aPCC due to higher efﬁcacy levels at 12, 24
and 36 hour time points. The results from a comparative trial
support the improved efﬁcacy rates associated with rFVIIa com-
pared to aPCC. CONCLUSIONS: In general, the studies do
report higher efﬁcacy and bleed cessation rates for rFVIIa than
for aPCC; however, the measurement of effectiveness of the
agents is open to interpretation due to variety of methods being
used to evaluate effectiveness. Further head-to-head trials should
incorporate a standardized measurement for deﬁning efﬁcacy.
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CONTRIBUTIONS OFTHE FABRY OUTCOME SURVEY (FOS)
TO ADVANCINGTHE MANAGEMENT OF FABRY DISEASE
Clarke J1, Beck M2, Giugliani R3, Sunder-Plassmann G4, Elliott P5,
Hernberg-Stahl E6, Mehta A7
1Hospital for Sick Children,Toronto, Ontario, Canada, 2University of
Mainz, Mainz, Germany, 3Hospital de Clinicas/UFRGS, Porto Alegre,
RS, Brazil, 4Medical University Vienna,Vienna, Austria, 5Heart Hospital,
London, UK, 6Shire HGT, Danderyd, Sweden, 7Royal Free Hospital,
London, UK
OBJECTIVES: To review how the Fabry Outcome Survey (FOS),
a physician-driven multinational database supported by Shire
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